C

oncerned about the outcome of some pharmaceutical company mergers and acquisitions, federal antitrust regulators have initiated a new policy toward asset sales that legal experts say may limit the pool of potential buyers and change the calculus for certain deals.

In general, the agency scrutinizes a merger or acquisition that creates two potentially worrisome scenarios. In the first, the acquiring company might shelve a pipeline product, squelching choices for patients. In the other, the acquiring company develops the medicine, but then might control the market for that type of product, assuming it has sufficient market share, and start charging higher prices.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy